Servicio de Cardiología, Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain.
Servicio de Cardiología, Hospital Universitario Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Pontevedra, Spain.
Rev Esp Cardiol (Engl Ed). 2022 Nov;75(11):911-922. doi: 10.1016/j.rec.2022.05.031. Epub 2022 Aug 1.
The diagnosis and management of mitral and tricuspid valve disease have undergone major changes in the last few years. The expansion of transcatheter interventions and widespread use of new imaging techniques have altered the recommendations for the diagnosis and treatment of these diseases. Because of the exponential growth in the number of publications and clinical trials in this field, there is a strong need for continuous updating of local protocols. The recently published 2021 European Society of Cardiology guidelines for the management of valvular heart disease did not include some of the new data on these new therapies and, moreover, the number of mitral and tricuspid interventions varies widely across Europe. Therefore, all this information must be summarized to facilitate its use in each specific country. Consequently, we present the consensus document of the Section on Valvular Disease, Cardiovascular Imaging, Clinical Cardiology, and Interventional Cardiology Associations of the Spanish Society of Cardiology for the diagnosis and management of mitral and tricuspid valve disease.
在过去的几年中，二尖瓣和三尖瓣疾病的诊断和管理发生了重大变化。经导管介入治疗的扩展和新成像技术的广泛应用改变了这些疾病的诊断和治疗建议。由于该领域的出版物和临床试验数量呈指数级增长，因此强烈需要不断更新本地方案。最近发布的 2021 年欧洲心脏病学会瓣膜性心脏病管理指南并未包含这些新疗法的一些新数据，此外，欧洲各地二尖瓣和三尖瓣介入治疗的数量差异很大。因此，必须总结所有这些信息，以方便在每个特定国家使用。因此，我们呈现了西班牙心脏病学会瓣膜疾病、心血管成像、临床心脏病学和介入心脏病学协会的共识文件，用于二尖瓣和三尖瓣疾病的诊断和管理。
